跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT03050593
NCT03050593已完成不适用

Prospective, Observational, Single-centre, Cohort Study Aimed at Developing Imaging and Plasma Biomarkers in Heart Failure With Preserved Ejection Fraction

University of Leicester0 个研究点目标入组 280 人开始时间: 2013年2月最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
280
主要终点
The composite end-point of all-cause mortality or repeat hospitalisation with heart failure
研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

The investigators wish to test a hypothesis that patients with HFpEF have different characteristics on echo, cardiac MRI and plasma protein & chemical profiles compared to HFrEF and healthy volunteers.

详细描述

Large scale prospective studies incorporating cardiac MRI, echocardiography and plasma sampling are currently lacking in HFpEF. The main aims of our study are to:

  1. better phenotype and characterise HFpEF (also comparing with HFrEF and age- and sex- matched healthy controls)
  2. provide mechanistic insights into pathophysiology
  3. describe potential biomarkers and their relation to relevant clinical outcomes (exercise capacity, heart failure quality of life and prognosis)

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
是

入选标准

  • •Clinical features of heart failure or prior radiographic evidence in the absence of symptoms And Either ejection fraction > 50% (for HFpEF arm) or ejection fraction < 40% (for HFrEF arm)

排除标准

  • •Myocardial infarction within the preceding 6 months
  • •Suspected or confirmed cardiomyopathy (e.g. hypertrophic, infiltrative)
  • •Suspected or confirmed constrictive pericarditis
  • •Significant native valve disease (≥ moderate severity)
  • •Known Significant lung disease (documented or FEV1< 30% or FVC < 50%)
  • •Non-cardiovascular co-morbidity likely to cause death within 6 months (e.g. malignancy)
  • •Significant renal failure (estimated GFR < 30 ml/min/m2)
  • •Patient inability to provide informed consent (e.g. dementia)

结局指标

主要结局

The composite end-point of all-cause mortality or repeat hospitalisation with heart failure

时间窗: Minimum 6 month follow-up

次要结局

  • Quality of life assessed by the Minnesota Living with Heart Failure Questionnaire(Through study completion, an average of 1 year)
  • The number of new clinical diagnoses detected by cardiac MRI(Through study completion, an average of 1 year)
  • Exercise capacity as assessed by the six-minute walk test(Through study completion, an average of 1 year)

研究者

申办方类型
Other
责任方
Sponsor

相似试验

进行中（未招募）
不适用
PACIFIC-PRESERVED : PhenomApping, ClassIFication, and Innovation for Cardiac Dysfunction - HF With PRESERVED LVEF StudyHeart Failure With Preserved Ejection FractionHeart Failure
NCT04189029Assistance Publique - Hôpitaux de Paris175
Unknown
不适用
The Performance of the Mologic Biomarker Panel in InfectionInfectionSepsis
NCT03217552Mologic Ltd600
已完成
不适用
A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHDFacioscapulohumeral Muscular Dystrophy
NCT01437345Cooperative International Neuromuscular Research Group53
进行中（未招募）
不适用
An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World ConditionsChronic Heart Failure With Reduced Ejection FractionWorsening Chronic Heart Failure
NCT06632483Bayer604
招募中
不适用
Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated BacteremiaStaphylococcus Aureus Bacteremia
NCT06574399Fundación Pública Andaluza para la gestión de la Investigación en Sevilla1,000